606 C → T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia

Cancer Letters

Volumn 135, Issue 1, 1998, Pages 67-71

  Steiner, Michael ^a   Hillenbrand, Mathias ^a   Borkowsi, Manuela ^a   Seiter, Hansjörg ^a   Schuff Werner, Peter ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Benign prostatic hyperplasia; NAD(P)H:quinone oxidoreductase; Polymorphism; Prostatic adenocarcinoma

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); CYTOSINE; THYMINE;

ALLELE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; COMPARATIVE STUDY; ENZYMOLOGY; GENETICS; PROSTATE TUMOR; TUMOR GENE;

ADENOCARCINOMA; ALLELES; CYTOSINE; FEMALE; GENES, NEOPLASM; GENOTYPE; HUMANS; MALE; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; THYMINE;

EID: 0033534239     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00269-9     Document Type: Article

References (25)

1. [1] D. Ross, H. Beall, R.D. Traver, D. Siegel, R.M. Phillips, N.W. Gibson, Bioactivation of quinones by DT-diaphorase: molecular, biochemical and chemical studies, Oncol. Res. 6 (1994) 493-500.
2. [2] R. Li, M.A. Bianchet, P. Talalay, L.M. Amzel, The three-dimensional structure of NAD(P)H:quinone reductase, a flavoenzyme involved in cancer chemoprevention and chemotherapy: mechanism of the two-electron reduction, Proc. Natl. Acad. Sci. USA 92 (1995) 8846-8850.
3. [3] C. Lind, P. Hochstein, L. Ernster, DT-diaphorase as a quinone reductase. A cellular control device against semiquinone and superoxide radical formation, Arch. Biochem. Biophys. 216 (1982) 178-185.
4. [4] P. Workman, Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase, Oncol. Res. 6 (1994) 461-475.
5. [5] S.A. Fitzsimmons, P. Workman, M. Grever, K. Paull, R. Camalier, A.D. Lewis, Reductase enzyme expression across the National Cancer Institute Tumor Cell Line Panel: correlation with sensitivity to mitomycin C and EO9, J. Natl. Cancer Inst. 88 (1996) 259-269.
6. [6] A.K. Jaiswal, O.W. McBride, M. Adesnik, D.W. Neben, Human dioxin-inducible NAD(P)H:menadione oxidoreductase. cDNA sequence and localization to chromosome 16, J. Biol. Chem. 263 (1988) 13572-13578.
7. [7] R.D. Traver, T. Horikoshi, K.D. Danenberg, T.H.W. Stadlbauer, P.V. Danenberg, D. Ross, N.W. Gibson, NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity, Cancer Res. 52 (1992) 797-802.
8. [8] P. Eiekelmann, W.A. Schulz, D. Rohde, B. Schmitz-Dräger, H. Sies, Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line, Biol. Chem. Hoppe-Seyler 375 (1994) 439-445.
9. [9] E.A. Rosvold, K.A. McGlynn, E.D. Lustbader, K.H. Buetow, Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking, Pharmacogenetics 5 (1995) 199-206.
10. [10] J.K. Wiencke, M.R. Spitz, A. McMillan, K.T. Kelsey, Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism, Cancer Epidemiol. Biomarkers Prev. 6 (1997) 87-92.
11. [11] W.A. Schulz, A. Krummeck, I. Rösinger, P. Eickelmann, C. Neuhaus, T. Ebert, B.J. Schmitz-Drager, H. Sies, Increased frequency of the null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies, Pharmacogenetics 7 (1997) 235-239.
12. [12] K.T. Kelsey, D. Ross, R.D. Traver, D.C. Christiani, Z.-F. Zuo, M.R. Spitz, M. Wang, X. Xu, B.-K. Lee, B.S. Schwartz, J.K. Wiencke, Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy, Br. J. Cancer 76 (1997) 852-854.
13. [13] D.W. Neben, R.A. McKinnon, A. Puga, Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer, DNA Cell Biol. 15 (1996) 273-280.
14. [14] A. Begleiter, M.K. Leith, T.J. Curphey, G.P. Doherty, Induction of DT-diaphorase in cancer chemoprevention and chemotherapy, Oncol. Res. 9 (1997) 371-382.
15. [15] A.M. Rauth, Z. Goldberg, V. Misra, DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis, Oncol. Res. 9 (1997) 339-349.
16. 609C → T mutation and rapid fractional excretion of chlorzoxazone, Cancer Res. 57 (1997) 2839-2842.
17. [17] L.W. Harries, M.J. Stubbins, D. Forman, G.C.W. Howard, C.R. Wolf, Identification of genetic polymorphism at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer, Carcinogenesis 18 (1997) 641-644.
18. [18] T. Shirai, A. Nakamura, S. Fukushima, A. Yamamoto, M. Tada, N. Ito, Different carcinogenic responses in a variety of organs, including the prostate, of five different rat strains given 3,2′-dimethyl-4-aminobiphenyl, Carcinogenesis 11 (1990) 793-797.
19. [19] P.G. Shields, N.E. Caporaso, R.T. Faulk, H. Sugimura, G.E. Trivers, B.F. Trump, R.N. Hoover, A. Weston, C.C. Harris, Lung cancer, race and a CYP1A1 genetic polymorphism, Cancer Epidemiol. Biomarkers Prev. 2 (1993) 481-485.
20. [20] F. Crofts, G.N. Cosma, D. Currie, E. Taioli, P. Toniolo, S.J. Garte, A novel CYP1A1 gene polymorphism in African-Americans, Carcinogenesis 14 (1993) 1729-1731.
21. [21] B.L. Kuehl, J.W.E. Paterson, J.W. Peacock, M.C. Paterson, A.M. Rauth, Presence of a heterozygous substitution and its relationship to DT-diaphorase activity, Br. J. Cancer 72 ( + ) (1995) 555-561.
22. [22] R.D. Traver, D. Siegel, H.D. Beall, R.M. Phillips, N.W. Gibson, W.A. Franklin, D. Ross, Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase), Br. J. Cancer 75 (1997) 69-75.
23. [23] P.Y. Gasdaska, H. Fisher, G. Powis, An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone binding site is present in human normal and tumor tissues, Cancer Res. 55 (1995) 2542-2547.
24. [24] L.T. Hu, J. Stamberg, S.S. Pan, The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C, Cancer Res. 56 (1996) 5253-5259.
25. [25] V. Radjendirane, P. Joseph, Y.H. Lee, S. Kimura, A.J.P. Klein-Szanto, F.J. Gonzalez, A.K. Jaiswal, Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity, J. Biol. Chem. 273 (1998) 7382-7389.